António Araújo

Prof. António Araújo

Centro Hospitalar Universitário do Porto, Porto, Portugal
+1
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2014
Verified
Book Chapter
Closed access
PDF file
MGMónica Gomes
Mónica Gomes
Ana Luísa TeixeiraAna Luísa Teixeira
Ana Luísa Teixeira
ACAna Coelho
Ana Coelho
AAAntónio Araújo
António Araújo
Rui MedeirosRui Medeiros
Rui Medeiros

1 May 2017 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
RPRut Porta
Rut Porta
RBRoberto Borea
Roberto Borea
ACAndreia Coelho
Andreia Coelho
SKShahanavaj Khan
Shahanavaj Khan
AAAntónio Araújo
António Araújo
Christian RolfoChristian Rolfo
Christian Rolfo

21 March 2017
Verified
Book Chapter
Closed access
PDF file
Christian RolfoChristian Rolfo
Christian Rolfo
CCChristian Caglevic
Christian Caglevic
MSMariacarmela Santarpia
Mariacarmela Santarpia
AAAntónio Araújo
António Araújo
Elisa GiovannettiElisa Giovannetti
Elisa Giovannetti
MMMauricio Mahave
Mauricio Mahave

23 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
STSimona Taverna
Simona Taverna
MGMarco Giallombardo
Marco Giallombardo
IGIgnacio Gil-Bazo
Ignacio Gil-Bazo
ACAnna Paola Carreca
Anna Paola Carreca
MCMarta Castiglia
Marta Castiglia
Christian RolfoChristian Rolfo
Christian Rolfo
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice

1 February 2007 in The Oncologist
Verified
Journal Article
Closed access
PDF file
AAAntónio Araújo
António Araújo
Ricardo Jorge RibeiroRicardo Jorge Ribeiro
Ricardo Jorge Ribeiro
IAIsabel Azevedo
Isabel Azevedo
ACAna Coelho
Ana Coelho
MSMarta Soares
Marta Soares
GSGiorgio V. Scagliotti
Giorgio V. Scagliotti
Learning Objectives: After completing this course, the reader will be able to: Describe the role played by EGF and EGFR in lung carcinogenesis.Discuss how different polymorphic alleles from the EGF and EGFR genes may affect drug response.Evaluate the value of determining the presence of EGF and EGFR polymorphisms in NSCLC patients for daily clinical practice.CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

6 March 2024 in ESMO Open
Verified
Journal Article
Open access
ABA. Barroso
A. Barroso
FEF. Estevinho
F. Estevinho
VHV. Hespanhol
V. Hespanhol
ETE. Teixeira
E. Teixeira
JRJoao Ramalho-Carvalho
Joao Ramalho-Carvalho
AAAntónio Araújo
António Araújo
Several anticancer therapies have the potential to cause infusion-related reactions (IRRs) in the form of adverse events that typically occur within minutes to hours after drug infusion. IRRs can range in severity from mild to severe anaphylaxis-like reactions. Careful monitoring at infusion initiation, prompt recognition, and appropriate clinical assessment of the IRR and its severity, followed by immediate management, are required to ensure patient safety and optimal outcomes. Lack of standardization in the prevention, management, and reporting of IRRs across cancer-treating institutions represents not only a quality and safety gap but also a disparity in cancer care. The present article, supported by recently published data, was developed to standardize these procedures across institutions and provide a useful tool for health care providers in clinical practice to recognize early signs and symptoms of an IRR and promptly and appropriately manage the event.